Neurogene是一家开发稀有疾病的治疗方法的生物技术公司, Neurogene, a biotech firm developing treatments for rare diseases, sees its stock rated "Buy" despite Q1 losses.

William Blair维持对Neurogene(NNE)的“外表”评分, Neurogene(NNE)是一家开发稀有神经疾病的治疗方法的生物技术公司。 William Blair maintains its "Outperform" rating for Neurogene (NGNE), a biotech firm developing treatments for rare neurological diseases. Neurogene的库存具有“Buy”共识评级,目标价格为59.80美元。 Neurogene's stock has a "Buy" consensus rating and a target price of $59.80. 公司股份于周二15.33美元开放。 The company's shares opened at $15.33 on Tuesday. NGN-401对雷特综合症进行NGN-401测试,NGN-101对CLN5 Batten疾病进行NGN-101测试。 Neurogene is testing NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. 尽管报告2025年第1季度收入(0.99美元)为EPS,但比预期高出0.05美元。 Despite reporting Q1 2025 earnings of ($0.99) EPS, it beat expectations by $0.05.